DBPapers
DOI: 10.5593/sgem2017/61/S25.084

DEVELOPMENT OF SYSTEMS FOR TARGETED DELIVERY OF INTERFERON ON THE BASIS OF CHITOSAN-ALGINATE NANOPARTICLES

N. Zhuravlyeva, A. Demshina, A. Krasnoshtanova, V. Panfilov
Tuesday 12 September 2017 by Libadmin2017

References: 17th International Multidisciplinary Scientific GeoConference SGEM 2017, www.sgem.org, SGEM2017 Conference Proceedings, ISBN 978-619-7408-12-6 / ISSN 1314-2704, 29 June - 5 July, 2017, Vol. 17, Issue 61, 641-648 pp, DOI: 10.5593/sgem2017/61/S25.084

ABSTRACT

Diabetes type I is one of the most important medical and social problem of health in all countries of the world. Treatment of diabetes type I diabetes is based on insulin therapy. Introduction α-2β interferon in addition to insulin therapy for patients with diabetes type I at the beginning of the disease can slow the progression of the disease and even achieve remission. Therefore, the purpose of this work was to develop a method of producing nanoparticles loaded with interferon for oral delivery systems of drugs. The optimum conditions for obtaining the biodegradable nanoparticles loaded with α-2- interferon with a size of 600-800 nm on the basis of the natural polymers alginate and chitosan wich provides pH-dependent release of immobilized protein were selected. It was shown that the nanoparticles release the encapsulated α-2β-interferon in an acidic environment of the stomach within 60 minutes no more than 15%. The main quality (78%) of the protein is released into the small intestine. It was shown by ELISA that immobilized in chitosan-alginate nanoparticles α-2β interferon retains its activity not less than 85%.

Keywords: diabetes, α-2β interferon, alginate, chitosan, nanoparticles, gastrointestinal tract.